Friday 6 November 2026 Export REGN’s income statement to Excel — free account

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.

Revenue: +36.3%
EPS: +36.0%
Free cash flow: +3.85%
Total debt: −26.6%

Quarter to September 2026, against a year earlier

909.45 6.55 +0.73%

Follow REGN

Alert me

Market cap: $93.4B
P/E: 19.2×
Fwd P/E: 19.2×
Dividend yield: 0.41%
F-score: 5/9
Altman Z: 7.49
Beneish M: −2.53
Dividend safety: 77/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Regeneron Pharmaceuticals, Inc. (REGN) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Regeneron Pharmaceuticals, Inc. (REGN) trades at a P/S ratio of 5.4×. Over the past ten years it has ranged from 3.5× (June 2022) to 18.0× (June 2015); the current reading is higher than 23% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/REGN/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Regeneron Pharmaceuticals, Inc. P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/REGN/metrics/ps-ratio">Regeneron Pharmaceuticals, Inc. (REGN) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	5.6×	4.01%
FY2024	5.4×	(26.48%)
FY2023	7.4×	16.13%
FY2022	6.3×	52.62%
FY2021	4.2×	(32.11%)
FY2020	6.1×	(2.16%)
FY2019	6.3×	(20.17%)
FY2018	7.8×	13.08%
FY2017	6.9×	(15.32%)
FY2016	8.2×	(40.01%)

Period	P/S ratio	Change
Sep 2026	4.6×	10.61%
Jun 2026	4.1×	(23.39%)
Mar 2026	5.4×	(4.32%)
Dec 2025	5.6×	37.68%
43 more quarters	Free account

Against its own ten years

Low 3.5× High 18.0×

Ten-year median 6.7×

Current reading's percentile 25

Company	P/S ratio
REGN Regeneron Pharmaceuticals, Inc.	5.4×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	6.6×
GMAB Genmab A/S Sponsored ADR compare	7.9×
ARGX argenex SE compare	9.5×
VRTX Vertex Pharmaceuticals Incorporated compare	10.6×
RPRX Royalty Pharma PLC compare	11.5×
MRNA Moderna, Inc. compare	43.2×
RVMD Revolution Medicines, Inc. compare	185×
ROIV Roivant Sciences Ltd. compare	3,528×
Biotechnology industry median	9.2×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Regeneron Pharmaceuticals, Inc. (REGN) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on REGN

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on REGN

Stockrow Weekly